
Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Companys lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cel... Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Companys lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.04 | -2.98507462687 | 1.34 | 1.4 | 1.2221 | 118996 | 1.33897213 | CS |
4 | -0.18 | -12.1621621622 | 1.48 | 1.53 | 1.2 | 312223 | 1.41140358 | CS |
12 | -0.92 | -41.4414414414 | 2.22 | 2.36 | 1.2 | 397252 | 1.72864854 | CS |
26 | -3.73 | -74.1550695825 | 5.03 | 5.86 | 1.2 | 359255 | 2.5849958 | CS |
52 | -3.73 | -74.1550695825 | 5.03 | 5.86 | 1.2 | 359255 | 2.5849958 | CS |
156 | -3.73 | -74.1550695825 | 5.03 | 5.86 | 1.2 | 359255 | 2.5849958 | CS |
260 | -3.73 | -74.1550695825 | 5.03 | 5.86 | 1.2 | 359255 | 2.5849958 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.